Tools
Stock profile

Aktis Oncology, Inc. (AKTS)

AKTS · Latest close $16.10 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$16.10
As of Nov 18, 2026
Tracked funds holding
4 of 149
2026 Q2 13F filings
Opened / added
1 / 0
vs previous quarter
Trimmed / exited
1
vs previous quarter

Aktis Oncology, Inc. (AKTS) is held by 4 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund opening new positions and 1 fund trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $258.6K sold). Latest close $16.10 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Sep 23, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-258.6K
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

RTW Investments · RA Capital Management · Baker Bros. Advisors — 4 tracked funds hold AKTS. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 2 sales ($258.6K). Insider trading

Often held alongside

Kodiak Sciences Inc. (KOD) · EVOMMUNE INC (EVMN) · Wave Life Sciences, Inc. (WVE) · XENCOR INC (XNCR) · Taysha Gene Therapies, Inc. (TSHA) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
RTW Investments0.44%1,592,043HELD Q3 filed Nov 16
RA Capital Management0.37%1,314,405TRIMMED (-12.6%) Q3 filed Nov 16
Baker Bros. Advisors0.16%996,351HELD Q3 filed Nov 16
Polen Capital Management0.02%63,514NEW Q3 filed Nov 13

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: -47.2% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

32.2313.882026-01-092026-11-18

Closing prices (unadjusted for dividends), last 2 years — 217 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding114 of 8,857 filers
Long-only filers among them114
Change vs 2026 Q1+49 net · 113 entered · 64 exited
Shares reported, all filers34,170,226
Reported value, all filers$1.0B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryPharmaceutical Preparations (SIC 2834)
Shares outstanding53,446,222
Market cap (at latest close)$860.5M

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jun 30, 2026.

Short interest

Shares short · Oct 15, 20264,313,744
Share of shares outstanding8.07%
Days to cover11.27

Shares short at recent settlements — Jul 31, 2026: 3.5M · Aug 14, 2026: 3.4M · Aug 31, 2026: 3.2M · Sep 15, 2026: 3.3M · Sep 30, 2026: 4.7M · Oct 15, 2026: 4.3M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jun 30, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jun 30, 2026.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 2 sales by 1 insider ($258.6K).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Sep 23, 2026Czibere AkosChief Medical OfficerSell5,099$20.19$103.0KSEC filing
Sep 23, 2026Czibere AkosChief Medical OfficerSell7,401$21.03$155.6KSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Sep 23, 2026Akos CzibereOfficer25,000$552.8KSep 23, 2026SEC filing
Jul 20, 2026KEN HERRMANNDirector4,856$119.3KJul 20, 2026SEC filing
Jul 17, 2026KEN HERRMANNDirector3,065$77.3KJul 17, 2026SEC filing
Jul 8, 2026AKOS CZIBEREOfficer50,000$1.4MJul 8, 2026SEC filing
Jul 8, 2026SHULAMIT RON-BIGGEROfficer50,000$1.4MJul 8, 2026SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

Activist disclosure · Schedule 13D

FiledFormPrice change since disclosure
Jan 20, 2026SCHEDULE 13D-20.1% (close Jan 21, 2026 → Nov 17, 2026)

Reference close is the first trading day after the filing (Jan 21, 2026). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
May 14, 2026Blue Owl Capital Holdings LPSC 13G3,161,3485.9%Mar 31, 2026SEC filing
Jan 20, 2026MPM BIOVENTURES 2018, L.P.SC 13D3,950,5287.4%Jan 12, 2026SEC filing
Jan 20, 2026EcoR1 Capital, LLCSC 13D4,824,4699.1%Jan 12, 2026SEC filing
Jan 15, 2026Eli Lilly and CompanySC 13D6,344,11411.9%Jan 12, 2026SEC filing
Jan 14, 2026Vida Ventures II, LLCSC 13D5,671,82510.6%Jan 12, 2026SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Screens & lenses

This stock does not currently pass any tracked screen.

Signal record

· Insider BEST — appeared in 1 of the last 20 quarterly lists; latest 2026 Q1, ranked #3 of 50.

Also held by the tracked funds that hold AKTS — ranked by lift, the co-holding pattern described in Methodology: Kodiak Sciences Inc. (KOD) · EVOMMUNE INC (EVMN) · Wave Life Sciences, Inc. (WVE) · XENCOR INC (XNCR) · Taysha Gene Therapies, Inc. (TSHA) · DISC MEDICINE INC (IRON) · Mirum Pharmaceuticals, Inc. (MIRM) · AVALO THERAPEUTICS INC (AVTX).

Recent 8-K filings

FiledItemsSource
Nov 12, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Aug 13, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
May 11, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

Kodiak Sciences Inc. (KOD) · Track Record: how the signals scored · Practice timing on AKTS

One email a week: the week’s new filings and research. Subscribe free

← AKAM  ·  ALAB →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.